Breast Cancer

Latest News


Video Series


Latest Videos


Shorts

The Reality of Biopsy Needle Conservation Requests
1:19
The Reality of Biopsy Needle Conservation Requests
6 days ago
by
Harriet Borofsky, MD
How the Brevera Recall Triggered a Supply Chain Cascade
1:15
How the Brevera Recall Triggered a Supply Chain Cascade
7 days ago
by
Harriet Borofsky, MD
Exploring the Weight Loss Potential of GLP-1 Agonists in Patients With Breast Cancer
0:51
Exploring the Weight Loss Potential of GLP-1 Agonists in Patients With Breast Cancer
a month ago
by
Sherry Shen, MD
How GLP-1 Agonists Improve Overall Survival in Breast Cancer Care
1:22
How GLP-1 Agonists Improve Overall Survival in Breast Cancer Care
a month ago
by
Sherry Shen, MD
ADC Vs Standard Chemo Selection in Breast Cancer
0:49
ADC Vs Standard Chemo Selection in Breast Cancer
2 months ago
by
Paolo Tarantino, MD, PhD
How Emotional Intelligence Can Reduce Physician Burnout
0:49
How Emotional Intelligence Can Reduce Physician Burnout
3 months ago
by
MinhTri Nguyen, MD
Addressing Bottlenecks to Cancer Care in Rural Settings
1:02
Addressing Bottlenecks to Cancer Care in Rural Settings
3 months ago
by
MinhTri Nguyen, MD
Are Oral SERDs Better Than Standard Therapy in Breast Cancer?
0:45
Are Oral SERDs Better Than Standard Therapy in Breast Cancer?
3 months ago
by
Sara M. Tolaney, MD, MPH
How AI is Helping Assess Breast Cancer Risk
0:29
How AI is Helping Assess Breast Cancer Risk
3 months ago
by
Elizabeth A. Mittendorf, MD, PhD
AI is Changing Breast Cancer Screening
1:05
AI is Changing Breast Cancer Screening
3 months ago
by
Cancer Network Staff

Podcasts


CME Content


More News

Using the DISCERN tool, LLMs (ChatGPT and OpenEvidence) scored significantly higher than Google on breast pathology health information quality and reliability, with mean total DISCERN scores of 62.2 and 64.8 vs 35.9, supporting integration of AI tools for patient education.

A prospective subsidized breast biopsy and navigation program at a Kenyan referral hospital achieved same-day CNB in 100% of 104 patients with invasive breast carcinoma, revealing high rates of aggressive subtypes and median 8-month prediagnostic delays, with 16.35% mortality during follow-up.

In 278 patients with a positive family history of breast cancer followed for a median 96 months, local recurrence, regional recurrence, and CBC risk were comparable to general population rates by SIR analysis, with recurrence risk driven more by biological subtype than family history.

In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

In this institutional retrospective review, 14.4% of clinically node-negative patients meeting SOUND trial criteria had nodal metastases on SLNB, underscoring the need for careful multidisciplinary decision-making before integrating axillary staging de-escalation into practice.